[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 555,430
  • Shares Outstanding, K 18,502
  • Annual Sales, $ 294,280 K
  • Annual Income, $ 367,020 K
  • EBIT $ 125 M
  • EBITDA $ 126 M
  • 60-Month Beta 1.20
  • Price/Sales 1.88
  • Price/Cash Flow 4.43
  • Price/Book 1.38

Options Overview Details

View History
  • Implied Volatility 61.19% (+3.67%)
  • Historical Volatility 60.78%
  • IV Percentile 12%
  • IV Rank 15.79%
  • IV High 142.67% on 03/24/26
  • IV Low 45.91% on 05/28/26
  • Expected Move (DTE 15) 2.97 (9.79%)
  • Put/Call Vol Ratio 1.07
  • Today's Volume 31
  • Volume Avg (30-Day) 127
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 3,950
  • Open Int (30-Day) 3,836
  • Expected Range 27.33 to 33.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.91
  • Number of Estimates 2
  • High Estimate $1.11
  • Low Estimate $0.70
  • Prior Year $3.28
  • Growth Rate Est. (year over year) -72.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.45 +19.06%
on 05/11/26
33.01 -8.21%
on 05/13/26
+0.90 (+3.06%)
since 05/01/26
3-Month
24.95 +21.44%
on 03/19/26
33.17 -8.65%
on 04/17/26
-2.72 (-8.24%)
since 03/03/26
52-Week
18.14 +67.03%
on 06/25/25
52.24 -42.00%
on 11/28/25
+9.91 (+48.60%)
since 06/03/25

Most Recent Stories

More News
Rigel to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress

SOUTH SAN FRANCISCO, Calif. , May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel Enters Exclusive Global Licensing Agreement for VEPPANUâ„¢ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer

SOUTH SAN FRANCISCO, Calif. , May 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel: Q1 Earnings Snapshot

Rigel: Q1 Earnings Snapshot

RIGL : 30.30 (+0.93%)
Rigel Reports First Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif. , May 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 30.30 (+0.93%)
Rigel's MDS Candidate Timeline Collides With Product Sales Momentum Question

Barchart Research What to Expect from RIGL Earnings RIGL Generated May 4, 2026 Current Price $29.54 EPS Estimate $$0.74 Consensus Rating Moderate Buy Average Move 17.65% Rigel's MDS Candidate Timeline...

RIGL : 30.30 (+0.93%)
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif. , April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its first quarter 2026 financial results after market...

RIGL : 30.30 (+0.93%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , April 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals,...

RIGL : 30.30 (+0.93%)
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC

RIGL : 30.30 (+0.93%)

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

3rd Resistance Point 33.90
2nd Resistance Point 32.50
1st Resistance Point 31.26
Last Price 30.30
1st Support Level 28.62
2nd Support Level 27.22
3rd Support Level 25.98

See More

52-Week High 52.24
Fibonacci 61.8% 39.21
Fibonacci 50% 35.19
Fibonacci 38.2% 31.17
Last Price 30.30
52-Week Low 18.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.